Celcuity Announces Clinical Trial Collaboration And Supply Agreement With Pfizer To Provide Ibrance(R) For Planned Phase 3 Clinical Trial
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it has entered into a
Celcuity Q3 EPS $(0.41) Misses $(0.31) Estimate
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.31) by 32.26 percent. This is a 105 percent decrease over losses of $(0.20) per share from the same
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Celcuity Announces Clinical Trial Collaboration With University Of Rochester Wilmot Cancer Center And Puma Biotechnology To Conduct Phase 2 Trial Of NERLYNX Plus XELODA
have metastatic HER2-negative breast cancer with brain metastases
The unique tumor insights CELsignia generates enable identification of new potential applications for targeted therapies and development of potential
ATyr Pharma, Celcuity Shares See Volume; Traders Circulate TipRanks Article Titled ‘2 Cutting-Edge Biotech Stocks That Can Double in Value (Or More)’ Mentioning Both Stocks
https://www.tipranks.com/news/article/2-cutting-edge-biotech-stocks-that-can-double-in-value-or-more
Canaccord Genuity Initiates Coverage On Celcuity with Buy Rating, Announces Price Target of $50
Canaccord Genuity analyst Arlinda Lee initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of $50.
